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Abstract
In the United States, Alzheimer’s disease (AD) is the most common cause of dementia, accompanied by substantial economic and
emotional costs. During 2015, more than 15 million family members who provided care to AD patients had an estimated total
cost of 221 billion dollars. Recent studies have shown that elevated total plasma levels of homocysteine (tHcy), a condition known
as hyperhomocysteinemia (HHcy), is a risk factor for AD. HHcy is associated with cognitive decline, brain atrophy, and dementia;
enhances the vulnerability of neurons to oxidative injury; and damages the blood–brain barrier. Many therapeutic supplements
containing vitamin B12 and folate have been studied to help decrease tHcy to a certain degree. However, a therapeutic
cocktail approach with 5-methyltetrahydrofolate, methyl B12, betaine, and N-acetylcysteine (NAC) have not been studied.
This novel approach may help target multiple pathways simultaneously to decrease tHcy and its toxicity substantially.
Keywords
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia that consists of decline in memory, language, and problemsolving skills. AD accounts for more than 50% of all clinically
diagnosed dementia.1 People in the final stages of AD are bed
bound and require constant care, ultimately leading to death.2
By 2050, a new case of AD is expected to occur every 33 s,
causing nearly 1 million new AD cases per year. The pathophysiology of AD involves neurons being damaged or
destroyed.2 After many years of research, studies have shown
that elevated homocysteine (Hcy) is a major risk factor. Hcy
promotes excitotoxicity and gives rise to neuronal DNA damage and apoptosis, thereby affecting short-term memory and
learning. It has become clear that elevated levels of Hcy elicit
neuronal death, including hippocampal and cortical neurons.1,3
Cross-sectional magnetic resonance imaging (MRI) studies
describe a similar correlation between high Hcy levels and
cerebral atrophy. The increased level of tHcy predicts the rate
of shrinkage of the medial temporal lobe in patients with AD.4

Hyperhomocysteinemia
(HHcy)/Oxidative Stress
HHcy is an elevation in blood levels of Hcy, a sulfurcontaining nonproteinogenic amino acid.5 Hcy is derived

from the hydrolysis of S-adenosyl Hcy during methionine
(Met) metabolism.6 Although Hcy is a normal metabolite,
Hcy excess is a risk factor for cognitive impairment and
dementia.7 HHcy has been associated with various adverse
health conditions including thrombosis, neuropsychiatric illness, fractures, and cardiovascular disease.8 While the serum
level of Hcy in healthy adults ranges from 5 to 10 mM, mild
Hcy ranges from 15 to 20 mM but can rise up to 500 mM, and
major symptoms have been shown to include neurodegenerative pathologies such as dementia, Parkinson’s disease (PD),
and AD.9 Reports show that older adults with HHcy have
more regional brain atrophy and reduced volumes of medial
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orbitofrontal cortices. In addition, they have thinner cortical
gray matter on MRI.10
Hcy is an excitatory amino acid that enhances the vulnerability of neurons to oxidative injury. Oxidative stress has
been implicated in the disease progression of AD and PD.
Oxidative stress is the cause of unregulated production of
reactive oxygen species (ROS). ROS can initiate neuronal
cell death, causing neurodegeneration. For example, highly
reactive hydroxyl radical is considered one of the ROS that
can subsequently lead to lipid peroxidation, protein oxidation, and protein aggregation.11–16 The brain is especially
susceptible to oxidative stress because of its relatively low
antioxidant enzymes.17 In addition, elevated total Hcy has an
increased risk for other disease, such as vascular diseases
and dementia.18
Furthermore, Hcy acts as a glutamate agonist on the
N-methyl-D-aspartate (NMDA) receptor. Overstimulation
of this receptor results in an increased level of cytoplasmic
calcium and higher production of free radicals and leads to
apoptosis.19–21 Intracerebroventricular injections of Hcy in
rats have induced lipid peroxidation, severe oxidative stress,
neuroinflammation, and cognitive impairment.22 HHcy also
affects the microvasculature and the blood–brain barrier
(BBB), which is more stringently controlled in the cortex.
The microcirculation of the brain is more susceptible to disruption by HHcy, which causes increased expression of
matrix metalloproteinases (MMPs). In the heterozygous
cystathionine-b-synthase (CBS) knockout mouse model, the
resulting HHcy increased brain permeability in relation to
increased MMP activity, extracellular matrix degradation,
vascular inflammation, and endothelial dysfunction. 22
Several proinflammatory agents, such as endotoxins, cytokines, and other oxidative stress factors, upregulate MMP
activity in astrocytes in vitro.22 The accumulation of toxic
free radicals plays a key role in BBB disruption via the
increased activity of MMPs.

pulmonary disease; helps treat human immunodeficiency
virus; improves neuropsychiatric disorders; and offers antioxidant, anti-inflammatory, mucolytic, and hepatoprotective
benefits.29–31 NAC itself is an amino-acid L-cysteine derivative; evidence supports that administering NAC helps reduce
oxidative damage in AD. 32 Oral NAC administration
increases cerebral spinal fluid (CSF) NAC concentrations,
with the highest total NAC concentration of 10.1 + 0.8 mM.33
GSH is depleted in the early stages of PD, and deficiency
has been demonstrated to perpetuate oxidative stress, mitochondrial dysfunction, and cell death.34 In the brain, GSH
depletion exacerbates oxidative stress, which is a pathogenesis of aging-related neurodegenerative diseases. Cysteine is
used to produce GSH.35,36 Research indicates that cysteine
uptake by excitatory amino acid carrier (EAAC1) is important for neuronal antioxidant function. A previous study
showed that mice lacking EAAC1/ show increased neuronal oxidative stress.37 However, this changed when oral
NAC treatment was initiated. In EAAC1/ mice, a model
of PD, NAC substantially reduced loss of dopaminergic neurons in the substantia nigra pars compacta,38 demonstrating
that NAC acts independently from the EAAC1 to cross the
neuronal membrane. Other research demonstrated that in
patients with major depressive disorder, supplementation
with NAC increased the NAC metabolite levels in the anterior cingulate cortex detected by proton magnetic spectroscopy, suggesting that NAC initiates its effects in the brain
region.39 Thus, NAC administration into the body may help
reduce the cytotoxicity caused by ROS generation. Furthermore, NAC may improve endothelial function through its
antioxidant properties, which may attenuate Hcy-induced
oxidative stress. NAC is well tolerated by most patients, with
only mild gastrointestinal symptoms such as flatulence and
diarrhea.24,39 These studies indicate that NAC can potentially
alleviate oxidative stress caused by HHcy. In addition, other
pathways are available for detoxifying Hcy further.

N-Acetylcysteine (NAC)

Hcy Trans-sulfuration and Remethylation

Glutathione (GSH) is a major endogenous antioxidant.
Several studies have implicated GSH redox imbalance in
AD and PD. Both animal models and humans with these
disorders have demonstrated altered levels of GSH and
oxidized GSH (GSSG), a decreased ratio of GSH/GSSG,
and/or impaired expressions or activities of GSH-related
enzymes in the brain.12,13,23
GSH deficiency is associated with many pathological
conditions. However, administering NAC, a cysteine prodrug, helps increase intracellular GSH levels. NAC supplies
the cysteine necessary for GSH synthesis.23–25 In particular,
NAC increases the GSH levels in the brain and alleviates
oxidative stress-associated damage.26 GSH has been implicated in the protection of brain cells against ROS.27 Indeed,
NAC is a remarkably active agent that has provided people
with relief in a variety of clinical settings.28 For example,
NAC reduces the duration of attacks of chronic obstructive

Hcy is detoxified in the cells via 2 pathways: transsulfuration and remethylation. With an excess cellular Hcy
level, trans-sulfuration converts Hcy into cystathionine with
the support of CBS. Cystathionine is then converted into
cysteine by cystathionine g-lyase.9,40 Mutations in genes
involved in Hcy metabolism, including CBS, can lead to
an increase in tHcy levels. Previous human tissue culture
research has demonstrated that Hcy concentration is
increased when Hcy metabolism is hindered by mutations
in the CBS gene. CBS-deficient (/) mice have 40-fold
higher total plasma Hcy levels.41–43
The remethylation pathway consists of Hcy being
remethylated back to Met. Hcy is recycled to Met by 2
enzymes, Met synthase (MS) and betaine-Hcy methyltransferase (BHMT). For both enzymes, the Hcy serves as an
acceptor of methyl groups for the maintenance of essential
S-adenosyl-met-dependent transmethylation reactions. MS
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Figure 1. The metabolic interactions between 5-methyltetrahydrofolate (5-MTHF), methylcobalamin (methyl-B12), N-acetylcysteine
(NAC), and betaine are shown targeting multiple pathways.

converts 5-methyltetrahydrofolate (5-MTHF), derived from
folic acid, into tetrahydrofolate using vitamin B12 as a
cofactor. Researchers have developed a genotype mouse
model with methyltetrahydrofolate reductase (MTHFR/)
deficiency and demonstrated that these mice have impaired
memory.44,45
The most common genetic abnormality for Hcy metabolism is a substitution at nucleotide 677 (C677T) of MTHFR.
With this genetic mutation, MTHFR activity will decrease
by 50%. In the Western countries, 9% to 17% of the population was homozygous for this mutation and 30% to 41%
was heterozygous.11,45,46 Homozygosity and heterozygosity
for the C677T mutation are the most common MTHFR variants and have been associated with high Hcy. Research has
shown that the C677T variant and plasma Hcy levels are
significant predictors of reduced regional brain volumes in
older adults. With decreased MTHFR, which is the ratelimiting enzyme in the methyl cycle, the level of 5-MTHF
production also decreases. 5-MTHF is a predominant form
of folate. 5-MTHF together with vitamin B12 is required for
the conversion of Hcy to Met by this pathway.10,47 Hcy can
also obtain a methyl group from betaine, catalyzed by
BHMT.48,49 BHMT-dependent remethylation of Hcy occurs
primarily in the liver, kidneys, and lens. The central nervous
system lacks BHMT and is therefore dependent on folate and
the vitamin B12 pathway for the conversion of Hcy into Met
(Figure 1), suggesting enhanced vulnerability of the brain to
HHcy. The regulation of BHMT has been shown to affect
Hcy concentrations in plasma.5,50

The MS and BHMT pathways of Hcy remethylation are
considered areas of interest for research when applying
the therapeutic cocktail approach to decrease Hcy levels and
its toxicity. Folic acid, vitamin B12, or betaine (trimethylglycine) can influence the Met-Hcy cycle and thus enhance
the conversion of Hcy into Met.50 Betaine has at least 5
different beneficial mechanisms for AD. First, betaine supplementation (6 g/d for 12 wk) decreased fasting plasma Hcy
by 9% in obese men and women.51 Second, betaine can
hinder the short- and long-term memory impairment induced
by Hcy. Memory function examinations such as Y-maze and
step-down-type passive avoidance test were used as measurements. Third, betaine can inhibit the Hcy-induced matrix
matrix metalloproteinase-9 (MMP-9) activity in the frontal
cortex, helping to prevent BBB damage.52 Fourth, betaine
can reduce hyperphosphorylation of tau protein, as hyperphosphorylation of tau protein causes neural fiber entanglement,
leading to neurodegeneration.53 Fifth, betaine treatment
restores expressions of synaptic proteins needed for synaptic
plasticity, which are vital to learning and memory.54 These
factual statements make betaine a promising novel strategy to
add in a therapeutic cocktail.

Methylcobalamin
Insufficient amounts of folate and vitamin B12 limit
the conversion of Hcy into Met, influencing the Hcy level.55
A vegetarian diet may cause deficiency in vitamin B12,
since this vitamin is found only in foods of animal origin.
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Moreover, acquired B12 deficiencies can result from parietal
cell and intrinsic factor antibodies (pernicious anemia),
malabsorption, age-related gut atrophy, or gastrectomy.56
Vitamin B treatment alleviates HHcy by 31.7% compared
with placebo. In effect, this was accompanied by a reduction
in the rate of brain atrophy of almost 30%. The prevalence of
vitamin B12 deficiency increases with age. Studies have
shown that there is a strong association between low B12
levels and risk of dementia. B12 is nontoxic, inexpensive,
and well tolerated.4,56,57
This study involved a clinical case of an 83-yr-old female
with a Mini–Mental State Examination score of 14, demonstrating a moderate degree of cognitive impairment. The
study showed that 10,000 mg of hydroxocobalamin had no
effect on reversing dementia. However, another therapeutic
trail of 3,000 mg methylcobalamin and 1,200 mg folic acid
daily was given.57 Within 2 wk, the patient’s cognition
improved slowly and normal behaviors returned. After 2 mo
of methylcobalamin and folic acid, the patient’s Mini–Mental
State Examination score was back to 29. The patient was
able to resume most of her previous activities and social
life.57 The patient’s cognitive impairment improved with
methylcobalamin and folic acid.57 The cause of relapse during
supplementation with hydroxocobalamin is likely an inability
to convert hydroxocobalamin into the metabolically active
form of methylcobalamin.57 Methylcobalamin ultimately
enters the MS pathway. Hcy accepts a methyl group from
methylcobalamin to be transformed into Met. Methylcobalamin is considered a substance that is biologically active at the
cellular level.58 This key point makes methylcobalamin a
more suitable choice to use in the therapeutic cocktail.

Conclusion
AD is the most common cause of dementia in the United
States and costs billions of dollars in health care. A substantial amount of research has demonstrated that HHcy leads to
cellular oxidative stress and is considered a risk factor for
developing AD. HHcy overstimulates NMDA and a-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors,
resulting in increased levels of cytoplasmic calcium, higher
production of free radicals, and activation of caspases, leading to cellular death. The accumulation of these toxic free
radicals plays a major role in BBB disruption through the
increased activity of MMPs. However, NAC can restore
intracellular GSH levels in the brain, reducing these free
radical toxicities. Oral NAC does produce an increase in
NAC concentration in the CSF.33 NAC also has shown many
other benefits in a variety of clinical settings.
Other alternative therapeutic approaches, such as activating the Hcy remethylation pathway, should also be considered for reducing oxidative stress. Both 5-MTHF and methyl
B12 are important additives for treating Hhcy, via the
remethylation pathway. Clinical evidence has shown that
using methylcobalamin can improve a patient’s Mini–Mental State Examination, and the patients are able to resume
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their normal daily activities. In addition, patients who have
the MTHFR gene C677T variant will have a decrease in
MTHFR enzyme activity, which ultimately decreases 5MTHF production.11,45 Therefore, adding 5-MTHF is beneficial. MS depends upon methyl B12 and 5-MTHF in the
remethylation pathway. In addition, Hcy is recycled to Met
through BHMT. Betaine supplementation has been shown to
decrease fasting plasma Hcy, improve memory, decrease
MMP activity, and decrease tau hyperphosphorylation.51–53
All 5-MTHF, methylB12, NAC, and betaine are available
separately as OTC dietary supplements. Therefore, one
should be able to make a therapeutic cocktail with 5MTHF, methyl B12, NAC, and betaine for AD treatment.
It will be more convenient for patients to have a cocktail
treatment rather than taking 4 different supplements. While
NAC helps alleviate oxidative stress, 5-MTHF, methyl B12,
and betaine can decrease Hcy concentration at the remethylation pathway. This combination of therapeutic cocktail can
potentially help AD pathophysiology by targeting multiple
areas simultaneously.
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